Oncogenesis (Oct 2022)

DUSP5P1 promotes gastric cancer metastasis and platinum drug resistance

  • Xiaohong Wang,
  • Lianhai Zhang,
  • Qiaoyi Liang,
  • Chi Chun Wong,
  • Huarong Chen,
  • Hongyan Gou,
  • Yujuan Dong,
  • Weixin Liu,
  • Ziyu Li,
  • Jiafu Ji,
  • Jun Yu

DOI
https://doi.org/10.1038/s41389-022-00441-3
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 11

Abstract

Read online

Abstract We elucidated the functional significance and molecular mechanisms of DUSP5P1 lncRNA (dual specificity phosphatase 5 pseudogene 1) in gastric carcinogenesis. We demonstrated that gastric cancer (GC) patients with high DUSP5P1 expression had shortened survival in two independent cohorts. DUSP5P1 promoted GC cell migration and invasion in vitro and metastasis in vivo. Mechanistically, DUSP5P1 activated ARHGAP5 transcription by directly binding to the promoter of ARHGAP5 with a binding motif of TATGTG. RNA-seq revealed that ARHGAP5 activated focal adhesion and MAPK signaling pathways to promote GC metastasis. DUSP5P1 also dysregulated platinum drug resistance pathway. Consistently, DUSP5P1 overexpression in GC cells antagonized cytotoxic effect of Oxaliplatin, and shDUSP5P1 plus Oxaliplatin exerted synergistic effect on inhibiting GC metastasis in vitro and in vivo. DUSP5P1 depletion also suppressed the growth of platinum drug-resistant PDO models. In conclusion, DUSP5P1 promoted GC metastasis by directly modulating ARHGAP5 expression to activate focal adhesion and MAPK pathways, serves as therapeutic target for platinum drug resistant GC, and is an independent prognostic factor in GC.